Short answer
Charles River Laboratories (CRL) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 fiscal 2026 financial results released for the period ended September 26, 2026.
Charles River Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 financial results released for the period ended September 26, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, guidance and operating drivers
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $982.7M, down 2.2% reported but organic growth 4.7%, signaling underlying demand recovery after divestitures
- Non-GAAP EPS $3.09, up 27.2%, with operating margin expanding 330 basis points to 23.0%
- DSA organic growth 5.9% and Manufacturing organic growth 7.4%, while RMS organic revenue declined 0.6%
- 2026 organic revenue guidance raised to at least +1.5%, and non-GAAP EPS guidance increased to $11.35-$11.55
- GAAP EPS $6.86 benefited from a $245.6M acquired tax-reserve reversal, limiting its recurring earnings significance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Charles River Laboratories 8-K filings
Get the next CRL 8-K as it lands
Follow CRL for push alerts, or ask the research agent what this filing means.